Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 383

1.

Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule.

Zehnder AF, Kristiansen AG, Adams JC, Merchant SN, McKenna MJ.

Laryngoscope. 2005 Jan;115(1):172-7.

PMID:
15630389
2.

Osteoprotegrin knockout mice demonstrate abnormal remodeling of the otic capsule and progressive hearing loss.

Zehnder AF, Kristiansen AG, Adams JC, Kujawa SG, Merchant SN, McKenna MJ.

Laryngoscope. 2006 Feb;116(2):201-6.

4.

Osteoprotegerin and rank ligand expression in prostate cancer.

Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, Vessella RL.

Urology. 2001 Apr;57(4):611-6.

PMID:
11306358
5.

Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.

Kraj M, Owczarska K, Sokołowska U, Centkowski P, Pogłód R, Kruk B.

Arch Immunol Ther Exp (Warsz). 2005 Sep-Oct;53(5):454-64.

PMID:
16314829
6.

RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.

Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM.

Rheumatology (Oxford). 2006 Sep;45(9):1068-76.

7.

Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure.

Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P.

Circulation. 2005 May 17;111(19):2461-8.

8.

[RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report].

Minenna G, D'Amore S, Maggiolini P, Scagliusi P, D'Amore M.

Recenti Prog Med. 2005 Sep;96(9):431-2. Italian.

PMID:
16229324
9.
10.
11.

Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.

Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA.

Cancer. 2006 Jul 15;107(2):289-98.

12.

Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?

Masi L, Simonini G, Piscitelli E, Del Monte F, Giani T, Cimaz R, Vierucci S, Brandi ML, Falcini F.

J Rheumatol. 2004 May;31(5):986-91.

PMID:
15124262
13.
14.

Differential gene expression in the otic capsule and the middle ear--an annotation of bone-related signaling genes.

Nielsen MC, Martin-Bertelsen T, Friis M, Winther O, Friis-Hansen L, Rye-Jørgensen N, Bloch S, Sørensen MS.

Otol Neurotol. 2015 Apr;36(4):727-32. doi: 10.1097/MAO.0000000000000664.

PMID:
25406873
15.

Detection of osteoprotegerin and TNF-alpha mRNA in ankylotic Stapes footplates in connection with measles virus positivity.

Karosi T, Jókay I, Kónya J, Szabó LZ, Pytel J, Jóri J, Szalmás A, Sziklai I.

Laryngoscope. 2006 Aug;116(8):1427-33.

PMID:
16885748
16.

Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice.

Maruyama K, Takada Y, Ray N, Kishimoto Y, Penninger JM, Yasuda H, Matsuo K.

J Immunol. 2006 Sep 15;177(6):3799-805.

17.
18.

Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.

Kaji H, Kanatani M, Sugimoto T, Chihara K.

Horm Metab Res. 2005 Oct;37(10):589-92.

PMID:
16278780
19.

Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study.

Bernstein CN, Sargent M, Leslie WD.

Inflamm Bowel Dis. 2005 Apr;11(4):325-30.

PMID:
15803021
20.

The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss.

Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, Wolf AM, Tilg H.

Gut. 2005 Apr;54(4):479-87.

Items per page

Supplemental Content

Support Center